Product Reports Resources Pricing Login Book a demo

Neumora Therapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2020 · IPO 2023

Neumora Therapeutics is pioneering the development of precision medicines for brain diseases, addressing the unmet needs in neuropsychiatric and neurodegenerative disorders. The company operates in the biopharmaceutical sector, focusing on Central Nervous System (CNS) diseases. Neumora's business model revolves around leveraging its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to develop targeted treatments. This approach aims to revolutionize the treatment landscape by focusing on novel mechanisms of action, rather than traditional drug classes. Neumora serves patients suffering from brain diseases, a market that affects over 1.5 billion people globally. The company generates revenue through the development and commercialization of its innovative drug pipeline, which is designed to offer more effective and targeted treatment options. Keywords: precision medicine, CNS diseases, neuropsychiatric, neurodegenerative, pharmacology, translational tools, clinical tools, computational tools, drug development, brain diseases.

Valuation $100–500M
Headcount 100–500
Total funding $500M–1B
Power Law Unicorn$1–10B valuation tier

Investors

20 investors on Neumora Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 16 investors entered at this stage
Amgen
ARCH Venture Partners
Altitude Life Science Ventures
Logos Capital
re.Mind Capital
Polaris Partners
Catalio Capital Management
Mubadala Capital
Surveyor Capital
Invus
F-Prime
Alexandria Venture Investments
Waycross Ventures
Exor
Abu Dhabi Growth Fund
Newpath Partners
Series B+ 4 investors entered at this stage
Exor
Newpath Partners
Abu Dhabi Growth Fund
Scripps Translational Science Institute

Global footprint

Where Neumora Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.8%
🇧🇷 Brazil1.3%
2 countries shown
Web traffic by country
9K monthly visits
across markets
🇺🇸 United States76.7%
🇨🇦 Canada14.4%
🇮🇳 India7.8%
🇫🇷 France1.1%
Top 4 markets shown

Talent graph

The shape of Neumora Therapeutics's talent

Dealroom maps Neumora Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

16 standout operatorsDealroom-flagged across the org
3 AI specialistspinpointed by name
106 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Neumora Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$38M patent portfolio · 30 active families

Estimated portfolio value
$38M
18.6% of market cap · 20.8× smaller than top peer BioNTech ($788M)
30 active patent families
Where Neumora Therapeutics innovates Computer programData miningMedicinal chemistryMedicineOpiate receptors

Where Neumora Therapeutics concentrates vs peers

Each axis is a top-10 topic across Neumora Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Neumora Therapeutics

An AI-synthesized read of the highest-engagement posts about Neumora Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neumora Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles